Effector Operating Income vs Total Operating Expenses Analysis
| EFTR Stock | USD 2.25 0.18 8.70% |
Effector Therapeutics financial indicator trend analysis is much more than just examining Effector Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Effector Therapeutics is a good investment. Please check the relationship between Effector Therapeutics Operating Income and its Total Operating Expenses accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.
Operating Income vs Total Operating Expenses
Operating Income vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Effector Therapeutics Operating Income account and Total Operating Expenses. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Effector Therapeutics' Operating Income and Total Operating Expenses is -0.55. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Effector Therapeutics, assuming nothing else is changed. The correlation between historical values of Effector Therapeutics' Operating Income and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Effector Therapeutics are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Operating Income i.e., Effector Therapeutics' Operating Income and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | -0.55 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Operating Income
Operating Income is the amount of profit realized from Effector Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Effector Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from Effector Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Effector Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.At this time, Effector Therapeutics' Issuance Of Capital Stock is relatively stable compared to the past year. As of 05/01/2024, Sales General And Administrative To Revenue is likely to grow to 3.47, while Selling General Administrative is likely to drop slightly above 10.1 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 31.9M | 32.4M | 33.7M | 33.6M | Cost Of Revenue | 24K | 53K | 111K | 105.5K |
Effector Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Effector Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Effector Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Effector Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Effector Stock
| 0.66 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.69 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.82 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Effector Stock
| 0.75 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.6 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.46 | HCM | HUTCHMED DRC | PairCorr |
The ability to find closely correlated positions to Effector Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Effector Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Effector Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Effector Therapeutics to buy it.
The correlation of Effector Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Effector Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Effector Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Effector Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Effector Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Effector Stock, please use our How to Invest in Effector Therapeutics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Effector Stock analysis
When running Effector Therapeutics' price analysis, check to measure Effector Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Effector Therapeutics is operating at the current time. Most of Effector Therapeutics' value examination focuses on studying past and present price action to predict the probability of Effector Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Effector Therapeutics' price. Additionally, you may evaluate how the addition of Effector Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |
Is Effector Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Effector Therapeutics. If investors know Effector will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Effector Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.37) | Revenue Per Share 0.349 | Quarterly Revenue Growth 1.17 | Return On Assets (0.85) | Return On Equity (9.47) |
The market value of Effector Therapeutics is measured differently than its book value, which is the value of Effector that is recorded on the company's balance sheet. Investors also form their own opinion of Effector Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Effector Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Effector Therapeutics' market value can be influenced by many factors that don't directly affect Effector Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Effector Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Effector Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Effector Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.